The Rise of Agentic AI and Self-Driving Laboratories: Reshaping Drug Discovery, Development, and Precision Medicine

The pharmaceutical sector is undergoing considerable transformation as a result of the integration of artificial intelligence (AI), automation, robotics, and advanced computing technologies. Traditional pharmaceutical discovery and development processes can be lengthy, costly, and associated with high failure rates, thereby necessitating more efficient approaches. Agentic artificial intelligence (Agentic AI) combines autonomous decision-making, goal-oriented reasoning, adaptive learning, and multi-step task execution. These capabilities may increase the autonomy and coordination of pharmaceutical research workflows. At the same time, self-driving or autonomous laboratories that utilize robotics, machine learning, laboratory automation, and real-time data analytics to conduct experiments with minimal or no human intervention have emerged as an alternative approach. Agentic AI can provide a higher-level orchestration layer for autonomous laboratories, while established approaches such as Bayesian optimization, active learning, machine learning, and robotic experimentation provide many of the underlying capabilities required for closed-loop experimentation. These technologies can be applied to drug discovery, lead optimization, formulation development, process optimization, and personalized medicine. Several challenges related to data quality, transparency, regulation, cybersecurity, ethical considerations, and infrastructure must be addressed before these systems can be widely adopted. In addition, current evidence is dominated by computational studies, research-scale proof-of-concept platforms, and early industrial implementations. Substantial uncertainty remains regarding their reproducibility, scalability, and effects on overall drug development timelines. Rather than representing an established replacement for conventional pharmaceutical research, the convergence of Agentic AI and autonomous laboratories should currently be regarded as an emerging systems-level architecture that builds upon established approaches such as Bayesian optimization, active learning, robotic experimentation, and closed-loop optimization. Its potential value lies in extending autonomy from individual computational or experimental tasks toward coordinated research workflows, although the extent of this added value remains to be established through prospective and end-to-end validation. Accordingly, fully autonomous pharmaceutical research should be regarded as a long-term research objective rather than an established technological capability, with its realization dependent on further advances in scientific reasoning, experimental validation, regulatory governance, cybersecurity, and human-AI collaboration.